BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25301744)

  • 1. Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.
    Deutsch S; Koerner P; Miller RT; Craft Z; Fancher K
    J Oncol Pharm Pract; 2016 Feb; 22(1):68-75. PubMed ID: 25301744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
    Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
    J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specialty pharmacy services for patients receiving oral medications for solid tumors.
    Stein J; Mann J
    Am J Health Syst Pharm; 2016 Jun; 73(11):775-96. PubMed ID: 27126828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated Cost and Savings in a Patient Management Program for Oral Oncology Medications: Impact of a Split-Fill Component.
    Staskon FC; Kirkham HS; Pfeifer A; Miller RT
    J Oncol Pract; 2019 Oct; 15(10):e856-e862. PubMed ID: 31465250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specialty pharmacy for hematologic malignancies.
    Fajardo S; Zook F; Dotson E
    Am J Health Syst Pharm; 2016 Jun; 73(11):797-809. PubMed ID: 27126835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction.
    Ribed A; Romero-Jiménez RM; Escudero-Vilaplana V; Iglesias-Peinado I; Herranz-Alonso A; Codina C; Sanjurjo-Sáez M
    Int J Clin Pharm; 2016 Apr; 38(2):280-8. PubMed ID: 26715547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions.
    Khandelwal N; Duncan I; Ahmed T; Rubinstein E; Pegus C
    J Natl Compr Canc Netw; 2012 May; 10(5):618-25. PubMed ID: 22570292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste.
    Looney B; Crumb J; White S; Jones G; Moore RP; Choi L; Zuckerman AD; Whelchel K
    J Manag Care Spec Pharm; 2024 May; 30(5):465-474. PubMed ID: 38701029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of an integrated oral chemotherapy program on patient adherence.
    Morgan KP; Muluneh B; Deal AM; Amerine LB
    J Oncol Pharm Pract; 2018 Jul; 24(5):332-336. PubMed ID: 28379068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents.
    Middendorff G; Elsey R; Lounsbery B; Chadwell R
    J Oncol Pharm Pract; 2018 Jul; 24(5):371-378. PubMed ID: 28509613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a formal pharmacist-run oral antineoplastic monitoring program: A pilot study in an adult genitourinary oncology clinic.
    Conliffe B; Figg L; Moffett P; Lauterwasser L; Parsons LB
    J Oncol Pharm Pract; 2019 Jun; 25(4):777-786. PubMed ID: 29375014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population.
    Divakaruni A; Saylor E; Duffy AP
    J Oncol Pharm Pract; 2018 Jul; 24(5):337-342. PubMed ID: 28387636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review.
    Snider M; Kalbfleisch S; Carnes CA
    Clin Ther; 2009 Jun; 31(6):1209-18. PubMed ID: 19695388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of clinical oral chemotherapy program on wastage and hospitalizations.
    Khandelwal N; Duncan I; Ahmed T; Rubinstein E; Pegus C
    Am J Manag Care; 2011 May; 17(5 Spec No):e169-73. PubMed ID: 21711067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program.
    Muluneh B; Schneider M; Faso A; Amerine L; Daniels R; Crisp B; Valgus J; Savage S
    J Oncol Pract; 2018 Jun; 14(6):e324-e334. PubMed ID: 29799768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a Pharmacist-Led Hypertension Management Program for Oral Chemotherapy in a Specialty Pharmacy Setting.
    Wang G; Truong H; Dang R
    J Oncol Pharm Pract; 2023 Jan; 29(1):52-59. PubMed ID: 34738845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center.
    Solomon JM; Ajewole VB; Schneider AM; Sharma M; Bernicker EH
    J Oncol Pharm Pract; 2019 Oct; 25(7):1564-1569. PubMed ID: 30170514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice.
    Holle LM; Puri S; Clement JM
    J Oncol Pharm Pract; 2016 Jun; 22(3):511-6. PubMed ID: 25900102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacists' performance of clinical interventions during adherence support medication reviews.
    Hatah E; Tordoff J; Duffull SB; Braund R
    Res Social Adm Pharm; 2014; 10(1):185-94. PubMed ID: 23688540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.